Visual Remapping for Age-Related Macular Degeneration

Recruiting in Palo Alto (17 mi)

Overseen byStephen Engel, Ph.D.

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Minnesota

No Placebo Group

Trial Summary

What is the purpose of this trial?Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.

Eligibility Criteria

This trial is for individuals aged 16 or older with central vision loss from age-related macular degeneration. Participants must have a stable gaze within one degree using their preferred retinal locus (PRL) and be able to calibrate an eye tracker. Those with cognitive impairment, poor fixation, or insufficient central vision loss are excluded.

Inclusion Criteria

You are able to use an eye tracker accurately.

No cognitive impairment as indicated by a Mini-Mental State Examination (MMSE).

I can keep my gaze steady using my preferred retinal location.

+2 more

Exclusion Criteria

It is not possible to properly calibrate the eye tracker for accurate measurements.

I have central vision loss but can still see directly in front of me.

Poor fixation (worse than+/- 1 deg) using their PRL.

+1 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

1 visit (in-person)

Initial Assessment and Calibration

Participants undergo visual field loss characterization, scotoma mapping, and eye tracker calibration

1 week

1 visit (in-person)

Personalized Remapping and Reading Tasks

Participants perform visual tasks and reading tasks with and without remapping over multiple sessions

6 weeks

6 visits (in-person)

Follow-up

Participants are monitored for any changes in reading performance and eye movement quality

1 week

1 visit (in-person)

Participant Groups

The study measures reading performance in patients with Central Vision Loss. It compares the effectiveness of traditional remapping versus personalized remapping of text to different visual fields in aiding reading.

2Treatment groups

Experimental Treatment

Active Control

Group I: Patients with scotomaExperimental Treatment2 Interventions

No remapping (control condition), traditional remapping, personalized remapping

Group II: Normally sighted with artificial scotomaActive Control2 Interventions

No remapping (control condition), traditional remapping, personalized remapping